HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., announced the closing of its previously announced acquisition of Dura Medical (Dura). This acquisition marks a significant step in building HOPE's network of interventional psychiatry clinics.
Dura Medical, with existing locations in Naples and Ft. Myers, Florida, was founded in 2018 and is a revenue-generating and EBITDA-positive entity. It offers a gold-standard approach to treating depression, PTSD, and chronic pain, utilizing procedures such as Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato, and Stellate Ganglion Blocks.
Stephen Durand, Dura's founder, has been appointed as Director of Florida Clinic Operations for HOPE. Dura's participation in the Veterans Affairs Community Cares Network (VA CCN) is critical, providing military veterans with access to interventional psychiatry programs. This acquisition, along with pending Neurospa TMS and Cohen and Associates acquisitions, is planned to provide services at more than 8 locations along the West Coast of Florida.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.